SGK2, 14-3-3 and HUWE1 cooperate to control the localization, stability and function of the oncoprotein PTOV1

This article was originally published here

Mol Cancer Res. 2021 Oct 15:molcanres.1076.2020. doi: 10.1158/1541-7786.MCR-20-1076. Online ahead of print.


PTOV1 is an oncogenic protein, initially identified in prostate cancer, that promotes proliferation, cell motility and invasiveness. However, the mechanisms that regulate PTOV1 remain unclear. In an effort to understand these mechanisms, we identify 14-3-3 as a PTOV1 interactor and show that high levels of 14-3-3 expression, like PTOV1, correlate with prostate cancer progression. Further, we discover an SGK2-mediated phosphorylation of PTOV1 at S36, which is required for 14-3-3 binding. Disruption of the PTOV1-14-3-3 interaction results in an accumulation of PTOV1 in the nucleus and a proteasome-dependent reduction in PTOV1 protein levels. To understand the effect of 14-3-3 on PTOV1 stability, we find that loss of 14-3-3 binding leads to an increase in PTOV1 binding to the E3 ubiquitin ligase HUWE1, which promotes proteasomal degradation of PTOV1. Conversely, our data suggest that 14-3-3 stabilizes PTOV1 protein by sequestering PTOV1 in the cytosol and inhibiting its interaction with HUWE1. Finally, our data suggest that stabilization of the 14-3-3-bound form of PTOV1 promotes PTOV1-mediated expression of cJun, which drives cell cycle progression in cancer. Together, these data provide a first mechanism to understand the regulation of the oncoprotein PTOV1. Implications: These findings identify a potentially targetable mechanism that regulates the oncoprotein PTOV1.

PMID:34654719 | DOI:10.1158/1541-7786.MCR-20-1076